Agilent Technologies (A) Stock

Agilent (A) shared its earnings report 30 days ago. What can we expect for the stock moving forward?

Investors should closely monitor Agilent (A) stock due to recent changes in the options market.

Padraig McDonnell, the CEO of Agilent, appears on 'Closing Bell Overtime' to discuss Investor Day, the company's healthcare division, and other topics.

A's stock benefits from the strong results of the Agilent CrossLab Group and its smart acquisitions.

Look into Agilent's (A) global revenue trends and how they affect Wall Street's predictions and the potential future of the stock.

Look into Agilent's (A) global revenue trends and how they affect Wall Street's predictions and the potential future of the stock.

A's results for the fourth quarter of 2024 are boosted by high demand in the ACG segment. However, there are worries due to falling sales in the Americas and China markets.

I maintain a "Buy" recommendation for Agilent Technologies, Inc., setting a target price of $150 per share for the next year, due to its strategic growth and market recovery. The purchase of BIOVECTRA will strengthen Agilent's CDMO business, particularly in oligonucleotides and CRISPR therapies, while also broadening its peptide synthesis services. For fiscal year 2025, Agilent expects core revenue growth of 2.5%-3.5% and adjusted EPS growth of 5.8%, which aligns with market expectations and is backed by targeted growth strategies in different segments.

The main figures for Agilent (A) provide an overview of the company's performance for the quarter that ended in October 2024. However, it could be helpful to compare some important metrics with Wall Street predictions and the results from the same period last year.